Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 14, 2023 12:04pm
96 Views
Post# 35223214

RE:New Twitter

RE:New Twitter Going back to Japan so quickly after the last trip is encouraging.  They may be following up on a potential investor or partner from their first vist. Let's hope we get some positive news from this trip.

It would be nice if we could get a clearer picture on the Dermaprecise timeline.  The Corporate update is almost 2 months old. In the update it makes reference to the submission to the FDA:

 "Once validation testing is completed, which we project will conclude before or during Q2 2023..."
That is a bit nebulous "before or during Q2"  could be February or it could be June.   I think the market needs a clearer picture.

Not much can be updated with the Shiseido Arbitration.  It is what it is.  I suspect by this point both sides have made their submissions.  It is now in the hands of the Arbitrator to review.  I am not sure how the Arbitration works but I assume each side get to review the other sides case.  Let's hope the Replicel's case is a strong one.  With the Hearing Date of May 29th announced Replicel predicts a ruling before the end of September.  Will it go that far ?  I am hoping that now each side has each others submission Shiseido's legal team suggest they settle and that come at any time.
<< Previous
Bullboard Posts
Next >>